SCHEMBL19786249

SCHEMBL19786249

O=C1NC(I)c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
HTR2B P41595 2/20 0.49
PARP1 P09874 1/20 0.49
HSD17B10 Q99714 2/20 0.47
TNKS2 Q9H2K2 7/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PBRM1 Q86U86 1/20 0.44
CYP1A2 P05177 1/20 0.41
GSK3B P49841 1/20 0.41
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
PARP3 Q9Y6F1 1/20 0.38
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29695366 0.74 TNKS2 (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL30179824 0.74 HSD17B10 (0.51) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL19573959 0.74 TNKS2 (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL19573960 0.74 TNKS2 (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL17201050 0.74 HTR2A (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL1708832 0.74 TNKS2 (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL4914352 0.74 HSD17B10 (0.51) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL31667419 0.74 TNKS2 (0.49) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL22397202 0.74 HSD17B10 (0.51) HTR2AHTR2CHTR2BPARP1HSD17B10
SCHEMBL29941489 0.74 HSD17B10 (0.51) HTR2AHTR2CHTR2BPARP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10646488-B2 Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof ARAXES PHARMA LLC (US) 2020-05-12 US disclosed
US-20180015087-A1 CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180015087-A1 CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS HTR2A 4187/4885HTR2C 4097/4885HTR2B 4555/4885
US-10646488-B2 Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof KRAS, NRAS, HRAS HTR2A 4187/4885HTR2C 4097/4885HTR2B 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.